MediFind

Find a Doctor

Jay H. Traverse

Allina Health System
Cardiology, Internal Medicine
Male
Practicing approx. 31 years

Bio


Jay Traverse is an Internal Medicine specialist and a Cardiologist in New Ulm, Minnesota. He has been an author on 95 peer reviewed articles and participated in 3 clinical trials in the past 15 years. Dr. Traverse's top three areas of expertise are Heart Attack, Angina, and Coronary Heart Disease. He is licensed to treat patients in MN.

Contact

New Ulm, MN 56073, US

Latest Research


Latest Advance
Study
  • Condition: Refractory Angina Pectoris (RAP)
  • Journal: The American journal of cardiology
  • Treatment Used: Ranolazine Therapy
  • Number of Patients: 158
  • Published —
This article evaluated ranolazine in patients with refractory angina pectoris (RAP).
Latest Advance
Study
  • Condition: Left ventricular function in cardiac disease
  • Journal: Journal of interventional cardiology
  • Treatment Used: Coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI)
  • Number of Patients: 2735
  • Published —
We sought to examine the impact of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) on left ventricular (LV) function.
Latest Advance
Study
  • Condition: Anthracycline-induced cardiomyopathy (AIC)
  • Journal: American heart journal
  • Treatment Used: SENCA (Stem cell injection in cancer survivors)
  • Number of Patients: 36
  • Published —
This phase I study was designed to evaluate the safety and feasibility of direct stem cell injection of allogenic mesenchymal stroma cells (allo-MSCs)delivered the heart for patients with anthracycline-induced cardiomyopathy (AIC).
Latest Advance
Study
  • Condition: Post-myocardial infarction heart failure.
  • Journal: American heart journal
  • Treatment Used: CardiAMP Heart Failure trial: High-dose autologous bone marrow mononuclear cell using CardiMAP cell therapy system.
  • Number of Patients: 0
  • Published —
This study evaluated the clinical outcomes in patients with post-myocardial infarction heart failure with high-dose autologous bone marrow mononuclear cell using CardiMAP cell therapy system.

Clinical Trials


Clinical Trial
Biological
  • Status: Recruiting
  • Study Type: Biological
  • Participants: 12
  • Start Date: November 20, 2019
Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart Failure
Clinical Trial
Biological
  • Status: Recruiting
  • Study Type: Biological
  • Participants: 3500
  • Start Date: April 25, 2017
Myocardial Ischemia and Transfusion

All Publications
View All


Publication
Study
  • Journal: Cardiovascular revascularization medicine : including molecular interventions
  • Published —
Coronary intravascular brachytherapy for recurrent coronary drug-eluting in-stent restenosis: A systematic review and meta-analysis.

Contact

New Ulm, MN 56073, US

Affiliations

  • Abbott Northwestern Hospital
  • New Ulm Medical Center
  • Ridgeview Medical Center
  • Hutchinson Health

Credentials

  • Graduate InstitutionClvlnd Clinic Lerner College Of Med Of Case Wstn Rsv University
    1989
  • Licenses
    Internal Medicine in MN
  • Board Certifications
    Cardiovascular Disease (Cardiology)
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.